- Home
- JXG vs RNAZ Comparison
JXG vs RNAZ Comparison
Compare JXG & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JXG | RNAZ |
|---|---|---|
| Founded | N/A | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4M | 8.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | JXG | RNAZ |
|---|---|---|
| Price | $4.20 | $9.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $280.00 |
| AVG Volume (30 Days) | 35.4K | ★ 135.5K |
| Earning Date | 11-05-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.26 | N/A |
| Revenue | ★ $46,835,624.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.82 | ★ N/A |
| Revenue Growth | ★ 21.68 | N/A |
| 52 Week Low | $3.01 | $6.08 |
| 52 Week High | $49.95 | $468.44 |
Technical Indicators
Market Signals| Indicator | JXG | RNAZ |
|---|---|---|
| Relative Strength Index (RSI) | 40.50 | 61.71 |
| Support Level | $4.01 | $8.35 |
| Resistance Level | $4.74 | $9.19 |
| Average True Range (ATR) | 0.68 | 0.77 |
| MACD | -0.28 | 0.27 |
| Stochastic Oscillator | 23.53 | 88.47 |
Price Performance
Historical ComparisonAbout JXG JX Luxventure Limited
JX Luxventure Group Inc is engaged in the tourism sector and supplying related products, including technology solutions, to business partners in China, both online and offline. The company operates in three segments Tourism products, Technology, and Cross board merchandise The majority of the group revenue is generated from Tourism products.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.